Allied Market Research

2024

Canadian Biosimilar Market

Canadian Biosimilar Market Size, Share, Competitive Landscape and Trend Analysis Report, by Type and, by Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

  • Sep 2024

  • Pages: NA

  • Tables: NA

  • Charts: NA

Select an option
Cloud Access (10% Off) $3,690 $3,321
Business User License (10% Off) $5,820 $5,238
Enterprise License (10% Off) $9,870 $8,883
Library Membership (15% Off) $1,175 $999
Enquiry Now
Author's: | Roshan Deshmukh
Publish Date:
Enquire Before Buying Customization Request Speak with Analyst

Get Sample to Email

  Canadian Biosimilar Market Report Highlights

Aspects Details
icon_5
By Type
  • HUMAN GROWTH HORMONE
  • ERYTHROPOIETIN
  • MONOCLONAL ANTIBODIES
  • INSULIN
  • INTERFERON
  • GRANULOCYTE-COLONY STIMULATING FACTOR
  • OTHERS
icon_6
By Application
  • BLOOD DISORDERS
  • ONCOLOGY
  • CHRONIC AND AUTOIMMUNE DISEASES
  • GROWTH HORMONE DEFICIENCIES
  • OTHERS
icon_7
Key Market Players

Celltrion/Hoffmann-La Roche, Biolyse Pharma, Medison, Mylan/Pfizer, PrimaPharm, Genscript Biotech Canada, Apobiologix, Teva Canada, BIOCAD, Sandoz Canada

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?
*Terms and Conditions Apply

Canadian Biosimilar Market

Global Opportunity Analysis and Industry Forecast, 2023-2032

help@alliedmarketresearch.com